Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers

Table 3 Frequent adverse events (> 1.0%)

Type of event	Treatment cycles N = 1851		Maximum number of repetitions
	N	%	Maximum number of repetitions
Pain at the administration site	402	21.7	24
Shivering	368	19.9	23
Burning sensation at the administration site	297	16.0	17
Chills	171	9.2	16
Local infection	70	3.8	4
Fever	42	2.3	7
Ulcer worsening*	30	1.6	2
Vomits	25	1.4	10

*:Reported by the doctors as adverse events. In fact, worsening of the ulcer as a therapeutic failure occurred in 209 cycles (11.3%).

ISSN: 2050-6511